AB0281 Reduction rate of rheumatoid factor reflects disease activity of rheumatoid arthritis. (12th June 2018)

• Record Type: Journal Article
• Authors: Okumura, N.; Kawasaki, T.; Yayama, T.; Kumagai, K.; Imai, S.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1320
• Page End: 1320
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.4496
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Rheumatoid factor (RF) is involved in the pathology of rheumatoid arthritis (RA) and its titer varies during the course of treatment with biological or synthetic DMARD. Objectives: In this study, we examined the relationship between RF change rate and disease activity. Methods: We analysed 287 RA patients (mean age 62.3 years; mean disease duration 13.1 years) in our hospital between 2015 and 2017, who were able to confirm the RF, and 3 groups were classified according to the change rate of RF for 1 year (92 in decreasing less than 80%, 114 in unchanged 80% or more, less than 120% and 81 in increasing 120% or more). We evaluated disease activity by simplified disease activity index(SDAI). Results: The drugs used are: MTX usage rate 63.1%, mean amount 3.81 mg, PSL usage rate 37.3%, mean amount 1.47 mg, biological drugs usage rate 48.8%. Disease activity change amount in 1 year (delta SDAI) was −0.88 (from 6.90 to 6.02). The median RF titer at baseline was 76 (27.5–178.5), the median RF change rate was 96% (71.5–125) and delta SDAI was significantly improved in the decreasing group (−1.97, 0.005, –0.04, p=0.0011). The swollen joint counts, tender joint counts, global assessment of evaluator and CRP were similarly improved significantly in this group. Conclusions: Although RF dose not decrease in all cases, it suggested that reduction rate of RF reflects disease activity. Disclosure of Interest: None declared